Granted Patent B2

US 9,314,429 · App. 14/837,493 · Granted Apr 19, 2016

Abstract

Claims (71)

1. A rapidly dispersible solid dosage form comprising a porous non-compressed three-dimensionally printed bound matrix comprising:

drug-containing particles having an average, median or mean effective particle size and comprising a first grade of oxcarbazepine (OXC) particles having an average, median or mean first native particle size, a second grade of OXC particles having an average, median or mean second native particle size, at least one disintegrant, at least one surfactant, and at least one binder;

at least one disintegrant; and

at least one binder; wherein

the dosage form disperses in 15 sec or less when placed in 15 ml of aqueous fluid; and

the ratio of average, median or mean effective particle size to average, median or mean, respectively, first native particle size ranges from a ratio that is greater than 1:1 to the ratio 5:1, and the ratio of average, median or mean effective particle size to average, median or mean respectively, second native particle size is 20:1 to 50:1.

2. A rapidly dispersible three-dimensionally printed porous non-compressed bound matrix comprising:

a first grade of OXC particles having an average, median or mean first native particle size, a second grade of OXC particles having an average, median or mean second native particle size, at least one sweetener, at least one binder, at least one disintegrant, at least one surfactant, and at least one glidant; wherein

the matrix comprises particles bound by binder;

the matrix disperses in less than 15 sec in a volume of 15 ml of aqueous fluid;

the OXC particles are included in drug-containing particles having an average, median or mean effective particle size and comprising the OXC particles and at least one pharmaceutical excipient as carrier;

the content of OXC in the matrix ranges from 35-60% wt based upon the total weight of the matrix; and

the ratio of average, median or mean effective particle size to average, median or mean, respectively, first native particle size ranges from a ratio that is greater than 1:1 to the ratio 5:1, and the ratio of average, median or mean effective particle size to average, median or mean respectively, second native particle size is 20:1 to 50:1.

3. The dosage form of claim 1 , wherein: a) OXC particles possess a bi-modal or multi-modal particle size distribution; b) the drug-containing particles possess a mono-modal, bi-modal or multi-modal particle size distribution; or c) a combination of one or more of the above.

4. The dosage form of claim 2 , wherein: a) the at least one surfactant is present in an amount ranging from 0.5-7.0% wt based upon the final weight of the dosage form; b) the at least one sweetener is present in an amount ranging from 0.01-2.0% based upon the final weight of the dosage form; c) the at least one binder is present in an amount ranging from 5-15% based upon the final weight of the dosage form; d) the at least one disintegrant is present in an amount ranging from 10-30% based upon the final weight of the dosage form; and/or e) the at least one glidant is present in an amount ranging from 0-2% based upon the final weight of the dosage form.

5. The dosage form of claim 1 , wherein: a) the hardness of the matrix ranges from about 1 to about 7 kiloponds (kp); b) the matrix disperses in 10 sec or less when placed in 15 ml of water or in saliva; c) binder is introduced into the matrix by way of printing fluid used to form the matrix; d) binder is introduced into the matrix by way of bulk powder used to form the matrix; e) the matrix comprises about 150 mg to about 600 mg of OXC; and/or f) the matrix comprises 10 to 40 three-dimensionally printed incremental layers.

6. The dosage form of claim 5 , wherein the thickness of an incremental layer ranges from 0.006 to 0.014 inches.

7. The dosage form of claim 1 , wherein the drug-containing particles further comprise sweetener and/or flavorant.

8. The dosage form of claim 1 , wherein: a) the content of drug-containing particles in the matrix ranges from 55-85% wt based upon the total weight of matrix in the final dosage form; b) the content of native particles of OXC in the drug-containing particles ranges from 55-85% wt based upon the final weight of the drug-containing particles; c) the content of disintegrant in the drug-containing particles ranges from 0-30% wt, based upon the final weight of the drug-containing particles; d) the content of binder in the drug-containing particles ranges from 0-10% wt, based upon the final weight of the drug-containing particles; e) the content of surfactant in the drug-containing particles ranges from 0-10% wt, based upon the final weight of the drug-containing particles; and/or f) the drug-containing particles are manufactured by wet granulation.

9. The dosage form of claim 1 , wherein the matrix comprises about 150 to about 1200 mg of OXC.

10. The dosage form of claim 1 , wherein the dosage form has been prepared by a three-dimensional printing process employing printing fluid, drug-containing particles and bulk powder of the following compositions:

Printing fluid

Water (% wt)

80-95

Glycerin (% wt)

0.5-20 

Alcohol (% wt)

0.1-20 

Surfactant (% wt)

0.01-10 

Sweetener (% wt)

 0-10

Binder (% wt)

 0-10

OXC Drug-containing particles:

OXC (% wt)

55-75

Disintegrant (% wt)

15-45

Binder (% wt)

 0-10

Surfactant (% wt)

 0-10

Bulk powder:

OXC containing particles (% wt)

55-65

Disintegrant (% wt)

 2-15

Binder (% wt)

20-45

Glidant (% wt)

 0.1-1.5.

11. The dosage form of claim 1 , wherein the dosage form has the following composition:

Oxcarbazepine (% wt)

 30-40 or

35-45

Disintegrant (% wt)

15-30

Binder (% wt)

30-55

Glidant (% wt)

0-5

Glycerin (% wt)

>0-20

Surfactant (% wt)

0-5

Sweetener (% wt)

 0-5.

12. The dosage form of claim 1 , wherein the dosage form is shaped as a wafer, cylinder, ring, donut, tube, cube, spheroid, ellipsoid or rectangular box.

13. The dosage form of claim 1 , wherein: a) the binder is selected from the group consisting of polyvinylpyrrolidone (povidone), mannitol, hydroxypropylcellulose, and a combination thereof; b) the disintegrant is selected from the group consisting of microcrystalline cellulose, a combination of two grades of microcrystalline cellulose, croscarmellose, and a combination thereof; or b) a combination of the above.

14. A method of treating a disease, condition or disorder that is therapeutically responsive to oxcarbazepine comprising administering the dosage form of claim 1 one to three times daily to a subject in need thereof throughout a treatment period.

Assignments (10)